trend of c-reactive protein and erythrocyte sedimentation rate in psoriatic patients under treatment of standard protocol of infliximab

background: psoriasis is a chronic and inflammatory dermatologic disease. inflammatory biomarkers such as c-reactive protein (crp) and erythrocyte sedimentation rate (esr) are known as immediate and delayed inflammatory biomarkers, respectively. due to the fact that anti-inflammatory drugs such as infliximab are widely used in psoriasis treatment, the aim of this study was to evaluate esr, crp and pasi scores in patients treated with infliximab in a 24 week trend. materials and methods: this study was accomplished as a before-after study. twenty seven psoriatic patients were included and standard infliximab therapy was applied. all patients underwent 3 times of blood collection and in each session crp, esr and pasi scores were measured at the beginning of study and at the 12th and 24th weeks of follow-up results: a total of 19 (70.4%) men and 8 (29.6%) women were evaluated. mean age was 37.85±13.68 years. all three parameters had significant decrease in treatment course (p<0.001); however, no significant correlation was found between pasi and inflammatory biomarkers. trends of esr and crp were significantly correlated in all patients (r=0.504, p =0.007) and males (r=0.739, p =0.036). conclusion: our study demonstrated that crp and esr decreased in infliximab treatment, in accordance but non-regarded to pasi score decease. regarding other studies results, using these biomarkers for treatment follow-up might need more caution. [gmj. 2015;4(1):8-13]